Liposomes were once touted as membranous “magic bullets” that would be modern, all-purpose carriers for drugs, enzymes, and genetic material. While this overoptimistic appraisal led to disappointment, researchers have found new applications for liposome technology and new ways to engineer liposomes to perform specific functions. These applications have attracted investment in several liposome-based companies and in research programs at multinational pharmaceutical houses. A number of liposome-based diagnostic, therapeutic, and veterinary products will soon face the test of the marketplace. Meanwhile, promising research results indicate that highly focused R&D programs could lead to a new generation of immune stimulants and anti-cancer agents based upon the liposome's ability to stimulate cellular processes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Wilson, T., Cave, L. New Commercial Opportunities for Liposomes Emerge. Nat Biotechnol 1, 148–154 (1983). https://doi.org/10.1038/nbt0483-148
Issue Date:
DOI: https://doi.org/10.1038/nbt0483-148